Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;2(11):100238.
doi: 10.1016/j.jtocrr.2021.100238. Epub 2021 Nov 29.

Correspondence Regarding "Tolerability of Coronavirus Disease 2019 Vaccines BNT162b2 and mRNA-1273 in Patients With Thymic Epithelial Tumors"

Kazuki Takada  1 , Shinkichi Takamori  2 , Naoko Miura  1 , Yasunori Shikada  1 , Mototsugu Shimokawa  3
Affiliations

Correspondence Regarding "Tolerability of Coronavirus Disease 2019 Vaccines BNT162b2 and mRNA-1273 in Patients With Thymic Epithelial Tumors"

Kazuki Takada et al. JTO Clin Res Rep. 2021 Nov.
No abstract available

PubMed Disclaimer

References

    1. Ballman M., Swift S., Mullenix C., et al. Tolerability of coronavirus Disease 2019 vaccines, BNT162b2 and mRNA-1273 in: patients with thymic epithelial tumors. JTO Clin Res Rep. 2021;2:100229. - PMC - PubMed
    1. Monin L., Laing A.G., Muñoz-Ruiz M., et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22:765–778. - PMC - PubMed
    1. Nelli F, Fabbri A, Onorato A, et al. Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study [e-pub ahead of print]. Ann Oncol. , accessed September 19, 2021. - DOI - PMC - PubMed
    1. Peeters M., Verbruggen L., Teuwen L., et al. Reduced humoral immune response after BNT162B2 COVID-19 MRNA vaccination in cancer patients under anti-neoplastic treatment. ESMO Open. 2021;6:100274. - PMC - PubMed
    1. Nishino M, Hatabu H, Ricciuti B, et al. Brief report axillary lymphadenopathy after COVID-19 vaccinations in patients with thoracic malignancy: incidence, predisposing factors, and imaging characteristics [e-pub ahead of print]. J Thorac Oncol. , accessed September 7, 2021. - DOI - PMC - PubMed